Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2019 · 10-Q
Revenue$4.93M$4.93M−56.0% vs Q2 2018 Net Income-$11.76M-$11.76MN/M vs Q2 2018 EPS Diluted-$0.24-$0.24— vs Q2 2018 Operating Income-$12,230,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$11,666,000N/M Margins · derivedOperating margin-247.9%−227.9 pt vs Q2 2018
Net margin-238.3%−236.5 pt vs Q2 2018
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end